New studies presented at the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) highlight the benefits newer treatments, including immunotherapy and targeted therapy, are having on patients with lung cancer. Read more here:
NY Times: lcrf.org/2HtwjVY